- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- August 2022
Global
From €1040EUR$1,090USD£872GBP
- Report
- August 2021
Global
From €3808EUR$3,990USD£3,191GBP
- Drug Pipelines
- August 2018
- 171 Pages
Global
From €20996EUR$22,000USD£17,592GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- April 2022
- 89 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- August 2022
- 510 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- January 2022
- 169 Pages
Global
From €3543EUR$3,712USD£2,968GBP
The Pulmonary Fibrosis Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat pulmonary fibrosis, a chronic and progressive lung disease. These drugs are used to reduce symptoms, slow the progression of the disease, and improve quality of life. Common treatments include corticosteroids, immunosuppressants, and antifibrotic agents. In some cases, lung transplantation may be recommended.
The Pulmonary Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of these companies include Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Novartis, and Vertex Pharmaceuticals. Show Less Read more
